Telitacicept completed domestic phase II clinical study on IgA Nephropathy

2021-08-10

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

2021-08-09

First clinical trial permit in Australia of Remegen! RC118, an ADC drug targeting the Claudin18.2

2021-07-30

RC48-ADC appeared on ASCO 2021 meeting again and brought exciting clinical data

2021-06-05

RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO

2020-06-17

荣昌生物房健民:做特立独行的ADC,找准适应症不扎堆

2020-04-04
Twitter Facebook 微博

Company Wechat

© All Right Reserved .  ICP:鲁ICP备11031710号-1